CCMR1 HTML TitleCCMR1DescriptionA double-blind, randomised placebo-controlled study of the safety & tolerability of a retinoid-X receptor agonist’s ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy: a phase 2a trial.StatusActivePIProf Siddharthan ChandranEdinburgh Imaging CollaboratorProf Adam WaldmanDiseaseMultiple Sclerosis (MS)Facility / resourceEIF RIEProject typeMulti-centre randomised placebo-control studyFundingAnne Rowling Clinic Relevant links28 Sep 17. MS studies This article was published on 2024-08-22
HTML TitleCCMR1DescriptionA double-blind, randomised placebo-controlled study of the safety & tolerability of a retinoid-X receptor agonist’s ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy: a phase 2a trial.StatusActivePIProf Siddharthan ChandranEdinburgh Imaging CollaboratorProf Adam WaldmanDiseaseMultiple Sclerosis (MS)Facility / resourceEIF RIEProject typeMulti-centre randomised placebo-control studyFundingAnne Rowling Clinic Relevant links28 Sep 17. MS studies
